LJP-394 equieffective to current immunosuppressive therapy in reducing anti-dsDNA antibodies Nov. 23, 2001
Regeneron proceeds to phase II trials with IL-1 Trap following promising phase I findings Nov. 22, 2001
Investigational anti-TNF antibody improves clinical measures of RA and joint destruction Nov. 22, 2001
RSS